Mass media information can facilitate early diagnose of hereditary angioedema: Case series study

Main Article Content

Isao Ohsawa*
Daisuke Honda
Yuya Nakamura
Hiromichi Gotoh
Yoshikazu Goto
Yusuke Suzuki
Yasuhiko Tomino

Abstract

Background: A patient’s motivation for consulting a physician is paramount to the first steps of achieving an early diagnosis of hereditary angioedema (HAE). Understanding what triggers this motivation can help in the design of strategies to increase the number of visits to a specialist physician following early symptoms of HAE. The aim of the present study was to identify the reasons that led patients to seek the opinion of an HAE expert physician.


Methods: The number of patients who had visited a specialist outpatient clinic for HAE was determined. All patients were asked what motivated them to seek medical consultation. Clinical data and blood samples were collected to establish a diagnosis.


Results: Seventy patients visited the clinic within a 30-month period between August 2015 and January 2018. Seven of these patients were diagnosed with HAE. The main source of evidence that prompted the visit to the specialist clinic was websites (67.1%), followed by newspapers (15.7%) and information provided by the home doctor (14.2%). The number of patients per month increased after a rise in the number of publications about HAE in newspapers and websites.


Conclusion: Mass media publications are an efficient way to motivate patients to visit an HAE expert physician.

Downloads

Download data is not yet available.

Article Details

Ohsawa, I., Honda, D., Nakamura, Y., Gotoh, H., Goto, Y., Suzuki, Y., & Tomino, Y. (2018). Mass media information can facilitate early diagnose of hereditary angioedema: Case series study. Global Journal of Medical and Clinical Case Reports, 5(3), 019–22. https://doi.org/10.17352/2455-5282.000063
Case Studies

Copyright (c) 2018 Ohsawa I, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.

We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.

Peertechz accomplice with- [CC BY 4.0]

Explanation

'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.

With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:

License Name

Permission to read and download

Permission to display in a repository

Permission to translate

Commercial uses of manuscript

CC BY 4.0

Yes

Yes

Yes

Yes

The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.

Zuraw BL. (2008) Clinical practice. Hereditary angioedema. New Eng J Med 359: 1027-1036. Link: https://goo.gl/29heGT

Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, et al. (2010) 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6: 24. Link: https://goo.gl/gjCndR

Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Cortellini G, et al. (2013) Clinical management of patients with a history of urticaria/angioedema induced by multiple NSAIDs: an expert panel review. Int Arch Allergy Immunol 160: 126-133. Link: https://goo.gl/JfRovV

He S, Tsang S, North J, Chohan N, Sim RB, et al. (1996) Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J Immunol 156: 2009-2013. Link: https://goo.gl/3VwJcs

Cicardi M, Bisiani G, Cugno M, Spath P, Agostoni A. (1993) Autoimmune C1 inhibitor deficiency: report of eight patients. Am J Med 95: 169-175. Link: https://goo.gl/b6PBQ4

Casali P, Borzini P, Pioltelli P, Invernizzi F, Zanussi C (1978) Acquired C1-Inhibitor Deficiency in Essential Cryoglobulinemia and Macrocryoglobnlinemia. Acta haematol 59: 277-284. Link: https://goo.gl/qaFy7T

Ghannam A, Defendi F, Charignon D, Csopaki F, Favier B, et al. (2013) Contact system activation in patients with HAE and normal C1 Inhibitor function. Immunol Allergy Clinics 33: 513-533. Link: https://goo.gl/5ot3zN

Ohsawa I, Honda D, Nagamachi S, Hisada A, Shimamoto M, et al. (2015) Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan. Annals of Allergy, Asthma & Immunology 114: 492-498. Link: https://goo.gl/N9FicU

Ohsawa I, Honda D, Hisada A, Inoshita H, Onda-Tsueshita K, et al. (2018) Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients. Intern Med 57: 319-324. Link:

Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, et al. (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114: S51-S131. Link: https://goo.gl/fJLwK5

Horiuchi T, Ohi H, Ohsawa I, Fujita T, Matsushita M, et al. (2012) Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research - secondary publication. Allergol int 61: 559-562. Link: https://goo.gl/coc1EY

Yamamoto T, Horiuchi T, Miyahara H, Yoshizawa S, Maehara J, et al. (2012) Hereditary angioedema in Japan: genetic analysis of 13 unrelated cases. Am J Med Sci 343: 210-214. Link: https://goo.gl/JRLVcj

Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, et al. (2018) The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy 73: 1575-1596. Link: https://goo.gl/59oQwN

Honda D, Ohsawa I, Sato N, Inoshita H, Mano S, et al.(2017) Diminished capacity of opsonization and immune complex solubilization, and detection of anti-C1q antibodies in sera from patients with hereditary angioedema. Allergol Int 66: 603-609. Link: https://goo.gl/43dwbP